['lymphoma, follicular']
['atezolizumab (mpdl3280a) [tecentriq]', 'lenalidomide', 'obinutuzumab']

        Inclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2

          -  Relapsed or refractory FL after treatment with at least one prior chemoimmunotherapy
             regimen that included an anti-CD20 monoclonal antibody and for which no other more
             appropriate treatment option exists as determined by the investigator

          -  Histologically documented CD20-positive lymphoma as determined by the local laboratory

          -  Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)

          -  At least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by
             CT scan or magnetic resonance imaging [MRI])

          -  Availability of a representative tumor specimen and the corresponding pathology report
             for retrospective central confirmation of the diagnosis of FL

          -  Agreement to comply with all local requirements of the lenalidomide risk minimization
             plan

          -  For women of childbearing potential: agreement to remain abstinent (refrain from
             heterosexual intercourse) or use two adequate methods of contraception, including at
             least one method with a failure rate of <1% per year, for at least 28 days prior to
             Day 1 of Cycle 1, during the treatment period (including periods of treatment
             interruption), and for at least 18 months after the last dose of study treatment

          -  For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use
             contraceptive measures and agreement to refrain from donating sperm for at least 3
             months after the last dose of study treatment

        Exclusion Criteria:

          -  Grade 3b follicular lymphoma

          -  History of transformation of indolent disease to diffuse large B-cell lymphoma (DLBCL)

          -  Known CD20-negative status at relapse or progression

          -  Central nervous system lymphoma or leptomeningeal infiltration

          -  Prior allogeneic stem-cell transplantation (SCT)

          -  Completion of autologous SCT within 100 days prior to Day (D) 1 of Cycle (C) 1

          -  Prior standard or investigational anti-cancer therapy as specified in protocol

          -  History of resistance to lenalidomide or response duration of <1 year

          -  Treatment with systemic immunosuppressive medications

          -  History of solid organ transplantation

          -  Clinically significant toxicity from prior therapy that has not resolved to Grade <=2
             (according to the National Cancer Institute Common Terminology Criteria for Adverse
             Events [NCI CTCAE], v4.0) prior to Day 1 of Cycle 1

          -  History of erythema multiforme, Grade >= 3 rash, or blistering following prior
             treatment with immunomodulatory derivatives such as thalidomide and lenalidomide

          -  Active bacterial, viral, fungal, or other infection

          -  Positive for hepatitis B surface antigen (HBsAg), total hepatitis B core antibody
             (HBcAb), or hepatitis C virus (HCV) antibody at screening

          -  Known history of HIV positive status

          -  History of progressive multifocal leukoencephalopathy

          -  History of autoimmune disease

          -  Contraindication to treatment for TE prophylaxis

          -  Grade <= 2 neuropathy

          -  History of other malignancy that could affect compliance with the protocol or
             interpretation of results

          -  Evidence of any significant, uncontrolled concomitant disease

          -  Inadequate hematologic function (unless due to underlying lymphoma)

          -  Abnormal laboratory values (unless due to underlying lymphoma)

          -  Pregnant or lactating or intending to become pregnant during the study
      